Who to call at Mangoceuticals, Inc., and when
Fundz watches for the moments Mangoceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day Mangoceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mangoceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Mangoceuticals, Inc.. With Fundz connected, it knows.
Mangoceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.mangorx.comThe seat is still open. No replacement has been named 361 days after this filing.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Mangoceuticals terminated Chief Operating Officer Amanda Hammer effective October 22, 2025, under a Separation Agreement signed October 27, 2025, which provides nine months of pay. The company also signed a 60-month office lease at 17130 Dallas Parkway, Dallas, Texas, starting November 1, 2025.
Key Takeaways
The COO departure is effective October 22, 2025, and the Separation Agreement was signed October 27, 2025, so the company disclosed the change five days after it was signed.
Hammer will receive a separation payment of nine months of her regular pay, paid in eight equal monthly installments starting November 1, 2025.
3 more takeaways
Related Filings (16)
16 more filings from Mangoceuticals, Inc. in the last 90 days
Filing Overview
What This Means
Mangoceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.